This trial will compare the efficacy of a new eye drop for treating dry eye disease caused by Graft-versus-Host Disease to the current standard of care.
- Graft Versus Host Disease (GVHD) of the Eye
- Graft-versus-Host Disease
1 Primary · 1 Secondary · Reporting Duration: Baseline to Week 4
Awards & Highlights
3 Treatment Groups
Standard of Care
1 of 3
1 of 3
1 of 3
30 Total Participants · 3 Treatment Groups
Primary Treatment: Lifitegrast 5% Ophthalmic Solution · Has Placebo Group · Phase < 1
Who is running the clinical trial?
Age 18 - 85 · All Participants · 2 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Does this clinical trial encompass participants who are over the age of 60?
"As per the conditions of this trial, those who meet its requirements must be aged 18 or older and 85 or younger." - Anonymous Online Contributor
How many individuals have registered for the research endeavor?
"Yes, clinicaltrials.gov indicates that this medical trial is currently in the recruitment phase. The study was first published on October 22nd 2022 and has since been updated as recent as November 11th 2022. Thirty patients are needed to be enrolled from 1 centre." - Anonymous Online Contributor
Are there any vacancies available in this trial for participants?
"Per clinicaltrials.gov, this trial is recruiting as of now and was initially posted on October 22nd 2022. The most recent edit to the posting occurred last month on November 11th 20202." - Anonymous Online Contributor
Is this an unprecedented research endeavor?
"Lifitegrast 5% Ophthalmic Solution has been on the research radar since 2022, when Novartis sponsored its first clinical trial with 30 participants. Subsequently, Lifitegrast 5% Ophthalmic Solution met Phase 1 drug approval standards and currently there is one active study being conducted under the sponsorship of Novartis." - Anonymous Online Contributor
Am I eligible for participation in this research study?
"To partake in this medical trial, applicants must have keratoconjunctivitis sicca and be within the age range of 18 to 85. A total of 30 patients are being sought for enrollment." - Anonymous Online Contributor
Are there any prior trials involving Lifitegrast 5% Ophthalmic Solution that we should be aware of?
"Presently, one clinical trial is underway to investigate the efficacy of Lifitegrast 5% Ophthalmic Solution and has progressed to Phase 3. A single medical centre in Bellaire, Texas is running the trials on this drug with no other sites involved." - Anonymous Online Contributor